No profile data available.
Curanex Pharmaceuticals Inc (CURX) is a healthcare company in the digestive system treatment drugs industry, based in Jericho, United States, with about 6 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$4.23 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $8.33 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout.
Curanex Pharmaceuticals reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$8.33 million as of October 9, 2026.
Listed companies of a similar size in the same industry (digestive system treatment drugs) include Heron Therapeutics, Inc. (HRTX), Evoke Pharma, Inc. (EVOK), Jaguar Health, Inc. (JAGX), Biodexa Pharmaceuticals Plc (BDRX).